Cannevert Scientist Accepted To Attend Bedrocan’s Masterclass On Medicinal Cannabis In Leiden, The Netherlands (March 2017)


Monday, February 6, 2017, Vancouver, B.C.


Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that Dr. Ricardo Rivera Acevedo, a scientist within its research arm, Cannevert Therapeutics Ltd., has been invited to attend the Masterclass on Medicinal Cannabis in Leiden, The Netherlands from March 5-10, 2017.

Bedrocan, a multinational company that has been growing and supplying pharmaceutical grade medicinal cannabis since the early 1980s, hosts this 5-day seminar yearly.  The selection process involves selecting from an international pool of applicants with diverse backgrounds and research interests from the industry.  Bedocran’s Head of Research and Education, Dr. Arno Hazekamp, has brought together several world experts to review the historical significance, regulatory status, chemical composition, clinical research designs, quality control/assurance matters, and latest cultivation techniques related to medicinal cannabis.


Read more



Veritas-Cannevert Commences Preparation of First Clinical Trials of Cannabis Targeting Pain


Tuesday, January 31, 2017, Vancouver, B.C.


Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that it is working with its research arm, Cannevert Therapeutics Ltd. to design and implement the first clinical trials of cannabis strains targeting pain.  Leading contract research organizations (CROs) with clinical experience of evaluating cannabis and pain are being considered for cost estimates and timelines.

Veritas CEO, Dr. Lui Franciosi indicated that, “Cannevert’s chemical and animal studies have identified suitable strains that warrant immediate human trials, which will be done to the highest standards at institutes of high repute”. Veritas and Cannevert intend to implement these clinical trials this year that meets the highest quality standards, i.e., Good Clinical Practices (GCPs).  CROs with experience in evaluating cannabis for the treatment of pain are currently being visited and screened for suitability.  Once a site is identified and a contract negotiated, a formal announcement will be made.


Read more


Veritas Announces Cannimed Ltd. As The New Supplier Of Cannabis Strains For Animal Studies

Wednesday, October 26, 2016, Vancouver, B.C.


Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that CanniMed Ltd. of Saskatoon, Canada, is the new supplier of cannabis strains for Cannevert Therapeutics Ltd (”CTL”) ongoing research. Veritas and CTL have entered this commitment in order to fulfill their mission to establish a sound scientific basis for the therapeutic uses of cannabis. With the vast number of compounds within the cannabis plant (more than 140 known cannabinoids), CTL will identify and develop the most effective cannabis strains for treatment of specific disease conditions such as chronic pain, cancer pain, PTSD, and emesis.


Veritas Pharma CEO, Dr. Lui Franciosi stated, “Thus far Cannevert Therapeutics has been successful in screening numerous strains in both their chemical and animal assays leading to identification of a few candidate strains. We believe access to a great variety of quality cannabis strains will be key to our success. CTL is excited to evaluate CanniMed’s specialized cannabis strains in Cannevert’s animal screens for analgesia.  CanniMed possesses two great qualities: a history of supplying standardized pharmaceutical-grade products and a continued interest in testing the efficacy of their cannabis strains. We share a similar vision in using an evidence-based approach in identifying what will be the most effective cannabis products.”


Read more


CANNEVERT DELIVERS ITS QUARTERLY RESEARCH REPORT;

A Number of Cannabis Strains Identified as Potentially Therapeutic


Tuesday, October 4, 2016, Vancouver, B.C.


Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces that it has received a quarterly research report from Cannevert Therapeutics Limited (CTL), lead researcher for Veritas. The report outlines both general and scientific progress since their last update.

Overall, CTL is a fully functional research company able to efficiently determine the amounts of cannabinoids present in different cultivars with precision and accuracy. This is to confirm that the materials received from cannabis suppliers have the purported characteristics, especially the cannabinoids of interest. In their initial animal studies, CTL has identified a number of cultivars with analgesic actions. They are now performing secondary screening, in particular, the collection of dose-response data for all pharmacological types of actions. The company continues to source more strains across Canada with potential therapeutic characteristics of interest. From a finance perspective, it has been fiscally responsible while ensuring that a six-month operational window is in place at all times. It’s funding has been improved by obtaining grants to help reduce research costs for personnel salaries. It has now accumulated a total of 16 committed personnel, comprising faculty, research associates, postdoctoral fellows, graduate students and co-op students. For the remainder of the year, Cannevert aims to acquire more skilled workers, identify further appropriate cultivars or mixtures of cultivars with therapeutic potential, and initiate planning for future clinical trials.


Read more



Health Canada Approval Received

​Wednesday, May 3, 2016, Vancouver, B.C.


Cannevert Therapeutics Ltd., the research partner of Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) has obtained an exemption from Health Canada to legally perform cannabis research.

“We’re pleased with Health Canada’s approval. Cannevert scientists can now begin the hard work of screening the various cannabis cultivars from Whistler Medical Marijuana Corporation,” explained Veritas CEO, Lui Franciosi.  Health Canada also granted permission for the scientists to use other controlled substances to better understand the effects of cannabis.


Read more



Cannevert Therapeutics Ltd. Delivers Its First Quarterly Scientific Progress Report

​Thursday, 7 April 2016, Vancouver, BC

Veritas Pharma Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) is pleased to announce that Cannevert Therapeutics Ltd. has delivered its first quarterly scientific progress report.

The report outlines the establishment and standardization of the chemical and pharmacological assays that will be used to screen new cannabis cultivars.  Veritas’ CEO, Dr. Lui Franciosi commented, “We are pleased with what the Cannevert team has achieved thus far within budget.  We think that the chemical and biological assays now in place will allow us to quickly process different cannabis strains over the coming months.”​

Read more



Veritas Presents Its Key Cannevert Scientists


Tuesday, 16 February 2016, Vancouver, BC

Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT) announced in a news release dated December 21, 2015, that the Company would invest in Cannevert Therapeutics Ltd. (“CTL”) to assist in the discovery and development of new cannabis cultivars for specific disease conditions. 

Below are the key Cannevert scientists:

Read more​



Veritas Pharma Names Whistler Medical Marijuana as Principal Supplier


Wednesday, 10 February 2016, Vancouver, BC

Veritas Pharma Inc (CSE: VRT), a Vancouver-based pharmaceutical company, announced today that the company has named Whistler Medical Marijuana Corp. as its principal supplier of cannabis cultivars. Veritas will purchase cannabis cultivars from Whistler, whom is licensed by Health Canada to produce dried or fresh marijuana as well as cannabis oil, over the next 18 months and supply it to Cannevert Therapeutics Ltd. for preclinical and clinical testing.

"The variety of cannabis that Whistler has to offer will ensure that Cannevert will have the best quality and quantity of material needed to conduct research,” said Dr. Lui Franciosi, CEO of Veritas Pharma.

Read more

Recent News

Cannevert Therapeutics